Bayer has signed a new and potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal of its kind for the German pharma in the past week.
The National Institutes of Health (NIH) has enlisted the help of 11 top-tier biopharma companies as it pushes towards the goal of cutting the time it takes to bring new cancer immunotherapies to patients in half.